172 related articles for article (PubMed ID: 38198446)
1. Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study.
Louchet M; Collier M; Beeker N; Mandelbrot L; Sibiude J; Chouchana L; Treluyer JM
PLoS One; 2024; 19(1):e0295897. PubMed ID: 38198446
[TBL] [Abstract][Full Text] [Related]
2. Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample.
Demailly R; Escolano S; Quantin C; Tubert-Bitter P; Ahmed I
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1126-1134. PubMed ID: 28758270
[TBL] [Abstract][Full Text] [Related]
3. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009.
van Gelder MM; Bos JH; Roeleveld N; de Jong-van den Berg LT
Hum Reprod; 2014 Jan; 29(1):161-7. PubMed ID: 24105826
[TBL] [Abstract][Full Text] [Related]
4. Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems.
Blotière PO; Damase-Michel C; Weill A; Maura G
Drug Saf; 2021 Dec; 44(12):1323-1339. PubMed ID: 34613596
[TBL] [Abstract][Full Text] [Related]
5. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
[TBL] [Abstract][Full Text] [Related]
6. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort.
Dathe K; Frank J; Padberg S; Hultzsch S; Beck E; Schaefer C
BMC Pregnancy Childbirth; 2022 Aug; 22(1):666. PubMed ID: 36028798
[TBL] [Abstract][Full Text] [Related]
7. Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study.
Quantin C; Yamdjieu Ngadeu C; Cottenet J; Escolano S; Bechraoui-Quantin S; Rozenberg P; Tubert-Bitter P; Gouyon JB
BJOG; 2021 Sep; 128(10):1575-1584. PubMed ID: 33590634
[TBL] [Abstract][Full Text] [Related]
8. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database.
Araujo M; Hurault-Delarue C; Sommet A; Damase-Michel C; Benevent J; Lacroix I
Therapie; 2021; 76(3):239-247. PubMed ID: 32736872
[TBL] [Abstract][Full Text] [Related]
9. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study.
Choi EY; Jeong HE; Noh Y; Choi A; Yon DK; Han JY; Sung JH; Choe SA; Shin JY
PLoS Med; 2023 Feb; 20(2):e1004183. PubMed ID: 36848338
[TBL] [Abstract][Full Text] [Related]
10. Common teratogenic medication exposures-a population-based study of pregnancies in the United States.
Wang Y; Smolinski NE; Thai TN; Sarayani A; Ewig C; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol MFM; 2024 Jan; 6(1):101245. PubMed ID: 38061552
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced congenital defects: strategies to reduce the incidence.
De Santis M; Carducci B; Cavaliere AF; De Santis L; Straface G; Caruso A
Drug Saf; 2001; 24(12):889-901. PubMed ID: 11735646
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
13. Drug prescribing before and during pregnancy in south west France: a retrolective study.
Crespin S; Bourrel R; Hurault-Delarue C; Lapeyre-Mestre M; Montastruc JL; Damase-Michel C
Drug Saf; 2011 Jul; 34(7):595-604. PubMed ID: 21663335
[TBL] [Abstract][Full Text] [Related]
14. Utilisation of teratogenic medicines before and during pregnancy in Australian women.
Raichand S; Pearson SA; Zoega H; Buckley NA; Havard A
Aust N Z J Obstet Gynaecol; 2020 Apr; 60(2):218-224. PubMed ID: 31397495
[TBL] [Abstract][Full Text] [Related]
15. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: An application to antiepileptic drug use in 4.9 million pregnant women in France.
Blotière PO; Weill A; Dalichampt M; Billionnet C; Mezzarobba M; Raguideau F; Dray-Spira R; Zureik M; Coste J; Alla F
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):763-770. PubMed ID: 29763992
[TBL] [Abstract][Full Text] [Related]
16. Use of drugs to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland between 2014 and 2018: analysis of Swiss healthcare claims data.
Gerbier E; Graber SM; Rauch M; Marxer CA; Meier CR; Baud D; Winterfeld U; Blozik E; Surbeki D; Spoendlin J; Panchaud A
Swiss Med Wkly; 2021 Nov; 151():w30048. PubMed ID: 34843179
[TBL] [Abstract][Full Text] [Related]
17. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.
Zhu Y; Bateman BT; Gray KJ; Hernandez-Diaz S; Mogun H; Straub L; Huybrechts KF
BMJ; 2020 May; 369():m1494. PubMed ID: 32434758
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
Vannappagari V; Thorne C;
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
[TBL] [Abstract][Full Text] [Related]
19. Prenatal Care Initiation and Exposure to Teratogenic Medications.
Winterstein AG; Wang Y; Smolinski NE; Thai TN; Ewig C; Rasmussen SA
JAMA Netw Open; 2024 Feb; 7(2):e2354298. PubMed ID: 38300617
[TBL] [Abstract][Full Text] [Related]
20. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.
van Gelder MM; de Jong-van den Berg LT; Roeleveld N
Hum Reprod; 2014 Jan; 29(1):168-83. PubMed ID: 24108217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
